Peter M.J. Quinn, PhD
Assistant Professor of Ophthalmology
Department: Ophthalmology
Graduate Group Affiliations
Contact information
F.M. Kirby Center for Molecular Ophthalmology
Stellar Chance Laboratories, Room 315
422 Curie Blvd.
Philadelphia, PA 19104
Stellar Chance Laboratories, Room 315
422 Curie Blvd.
Philadelphia, PA 19104
Education:
BSc (Biological Sciences)
University of Manchester, 2008.
MSc (Molecular Medicine and Cancer Research)
Brunel University, 2011.
PhD (Department of Ophthalmology)
Leiden University Medical Center, 2019.
Permanent linkBSc (Biological Sciences)
University of Manchester, 2008.
MSc (Molecular Medicine and Cancer Research)
Brunel University, 2011.
PhD (Department of Ophthalmology)
Leiden University Medical Center, 2019.
Description of Research Expertise
Research Interests: Mechanisms and therapeutics for retinal degenerative diseases.Keywords: cell polarity, neurodegeneration, gene therapy, gene augmentation, CRISPR/CAS, gene editing, prime editing, induced pluripotent stem cells (iPSCs), organoids, inherited retinal diseases (IRDs), retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), autosomal dominant optic atrophy (ADOA), genetic glaucoma.
Research Details: The labs focus is to provide clinically translatable impact using iPSC-derived ophthalmic organoid-based approaches for the understanding and treatment of retinal degenerative diseases. The PrimeSight team are currently developing gene-specific and gene-agnostic therapeutics for the amelioration of the phenotypic, histopathological, and molecular changes in several inherited retinal disease iPSC-derived retinal organoid models. Further, they are establishing projects on autosomal dominant optic atrophy and genetic glaucoma.
Selected Publications
Costa BLD, Quinn PMJ, Wu WH, Nolan ND, Liu S, Wang NK, Demirkol A, Caruso SM, Tsai YT, Kong Y, Cabral T, Belfort R, Tsang SH. : Downregulation of miR-181a/b reprograms the retinal pigment epithelium metabolism in a mouse model of retinitis pigmentosa. Cell and Bioscience. 2024.Stehle IF, Imventarza JA, Woerz F, Antony S, Hoffmann F, Boldt K, Beyer T, Quinn PMJ, Ueffing M. : Human CRB1-CRB2 interaction support CRB2 as a modifier in CRB1-associated retinal diseases. Life Science Alliance. 2024.
Buck TM, Quinn PMJ, Pellissier LP, Mulder AA, Jongejan A, Koot D, Almushattat H, Arendzen CH, Vos RM, Bradley EJ, Freund C, Mikkers HMM, Boon CJF, van Kampen AH, Baas F, Koster AJ, Neefjes J, Berlin I, Jost CR, Wijnholds J. : CRB1 is required for recycling by RAB11A+ vesicles in human retinal organoids. Stem Cell Reports 18, September 2023.
Caruso SM, Tsai YT, da Costa BL, Kolesnikova M, Jenny LA, Tsang SH, Quinn PMJ.: Prime Editing Strategy to Install the PRPH2 c.828+1G>A Mutation. Adv Exp Med Biol 1415(1): 97-102, July 2023.
Tsai YT, da Costa BL, Caruso SM, Nolan ND, Levi SR, Tsang SH, Quinn PMJ.: Generation of an Avian Myeloblastosis Virus (AMV) Reverse Transcriptase Prime Editor. Adv Exp Med Biol 1415: 109-114, July 2023.
Lopes da Costa B, Kolesnikova M, Levi SR, Cabral T, Tsang SH, Maumenee IH, Quinn PMJ.: Clinical and Therapeutic Evaluation of the Ten Most Prevalent CRB1 Mutations. Biomedicines 11: 385, Jan 2023.
Balasubramanian R, Min X, Quinn PMJ, Giudice QL, Tao C, Polanco K, Makrides N, Peregrin J, Bouaziz M, Mao Y, Wang Q, da Costa BL, Buenaventura D, Wang F, Ma L, Tsang SH, Fabre PJ, Zhang X.: Phase transition specified by a binary code patterns the vertebrate eye cup. Sci Adv 7: eabj9846, Nov 2021.
Manafi N, Shokri F, Achberger K, Hirayama M, Mohammadi MH, Noorizadeh F, Hong J, Liebau S, Tsuji T, Quinn PMJ, Mashaghi A.: Organoids and organ chips in ophthalmology. Ocul Surf 19: 1-15, January 2021.
da Costa BL, Levi SR, Eulau E, Tsai YT, Quinn PMJ.: Prime Editing for Inherited Retinal Diseases. Front Genome Ed 3: 775330, Nov 2021.
Quinn PM, Buck TM, Mulder AA, Ohonin C, Alves CH, Vos RM, Bialecka M, van Herwaarden T, van Dijk EHC, Talib M, Freund C, Mikkers HMM, Hoeben RC, Goumans MJ, Boon CJF, Koster AJ, Chuva de Sousa Lopes SM, Jost CR, Wijnholds J.: Human iPSC-Derived Retinas Recapitulate the Fetal CRB1 CRB2 Complex Formation and Demonstrate that Photoreceptors and Müller Glia Are Targets of AAV5. Stem Cell Reports 12: 906-919, May 2019.